neuroscienceCME Medical Simulation
Premiere Date: Friday, April 3, 2009
Patient Info:
John is a 23-year-old male who recently completed 2 weeks of inpatient treatment for an acute psychotic episode. He has a personal and family history of alcohol dependence. He is consulting with his psychiatrist about possible treatment options upon discharge.This activity offers CE credit for:
All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
- Physicians (ACCME/AMA PRA Category 1)
- Pharmacists (ACPE)
Credit Expiration Date:
Saturday, April 3, 2010
Faculty
Rakesh Jain, MD, MPH
Director, Adult and Child Psychopharmacology Research
R/D Clinical Research, Inc.
Lake Jackson, TXStatement of Need
Substance dependence is a common comorbidity in patients with psychiatric illness, and is associated with poorer long-term outcomes related to lower treatment adherence, increased number of relapses, higher symptom severity, and sociological factors such as poor housing, employment status, and economic situations.(1) Differential diagnosis of schizophrenia in patients with possible drug-induced symptoms is challenging but vital to appropriate management; conversely, appropriate assessment and diagnosis of substance use disorder also is required to develop a treatment plan that takes into account both psychotic symptoms and alcohol and/or drug abuse. Long-term management of dually diagnosed patients requires a multifactorial approach including pharmacologic, nonpharmacologic, and psychosocial strategies designed to manage both psychotic symptoms and substance abuse. There are a number of choices for the pharmacologic management of psychotic symptoms, and selection of an appropriate agent must take into account comorbid substance use, issues with non-adherence, side effects, and concomitant medications. There are a number of FDA-approved agents available to help treat alcohol dependence but each of these medications has benefits and limitations that must be considered with respect to the particular clinical picture of the individual patient. For patients who abuse other substances, behavioral strategies have been shown to be effective, and the need for intensive behavioral intervention is a key consideration in selecting a long-term treatment plan.
- Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: Pharmacotherapeutic intervention. J Subst Abuse Treat 2008;34:61-71.
Activity Goal
To provide mental healthcare practitioners with clinically focused strategies drawn from the evidence base for assessing, diagnosing, and treating patients with schizophrenia and comorbid substance use disorder(s).
Learning Objectives
At the end of this CE activity, participants should be able to:
- Differentiate schizophrenia from other potential bases for psychosis in patients with substance use disorder.
- Identify the impact of dual diagnosis on the outcomes of patients.
- Develop an evidence-based, individualized long-term treatment plan for patients with dually diagnosed schizophrenia and substance abuse.
Target Audience
Physicians, physician assistants, and other healthcare professionals with an interest in mental health.
Financial Support
CME Outfitters, LLC, gratefully acknowledges an educational grant from No Commercial Supporter in support of this CE activity.
Credit Information
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs)
Universal Program Number: 376-000-09-010-H01-P
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.Rakesh Jain, MD, MPH
Rakesh Jain, MD, MPH, is Director of Psychiatric Drug Research for the R/D Clinical Research Center at Lake Jackson, Texas.
Dr. Jain attended medical school at the University of Calcutta in India. He then attended graduate school at the University of Texas School of Public Health in Houston, where he was awarded a National Institute/Center for Disease Control Competitive Traineeship. His research thesis focused on alcohol abuse issues. He graduated from the School of Public Health in 1987 with a Masters of Public Health (MPH) degree.
After graduate school, Dr. Jain completed a postdoctoral fellowship in Research Psychiatry with the Gerontology Center of the University of Texas Mental Sciences Institute in Houston. He received the National Research Service Award for the support of the postdoctoral fellowship. After this, he served a three-year residency in Psychiatry at the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical School at Houston as well as a two-year fellowship in Child and Adolescent Psychiatry.
Dr. Jain is currently involved in multiple research projects studying the effects of medications on short-term and long-term treatment of depression, anxiety, pain/mood overlap disorders, and psychosis in adult and child/adolescent populations. He is the author of several articles on the issue of mood and pain conditions. He serves on several Boards focusing on drug development and disease state education. He was recently named “Public Citizen of the Year” by the National Association of Social Workers, Gulf Coast Chapter, in recognition of community and peer education and championing of mental health issues. He was also recently awarded the “Extra Mile Award” by the local school district, in recognition of the service to the children of the school district and consultation to the teachers and counselors.Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Jain has disclosed that he receives research support from Abbott Laboratories, Addrenex Pharmaceuticals, Inc., Aspect Medical Systems, Inc., Forest Laboratories, Inc., Eli Lilly and Company, and Pfizer Inc. He is on the speakers bureaus of Cyberonics, Inc., GlaxoSmithKline, Jazz Pharmaceuticals, Eli Lilly and Company, Pfizer Inc., Shire Pharmaceuticals, and Takeda Pharmaceuticals North America, Inc. Dr. Jain serves as a consultant to Addrenex Pharmaceuticals, Inc., IMPAX Laboratories, Inc., Eli Lilly and Company, and Shire Pharmaceuticals.Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, Wyeth Pharmaceuticals, and Solvay Pharmaceuticals do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PL-010-040309-00
|
||||
 |
 |
 |
||
   |
||||
         
|
|
|||||||||
|
||||||||||
